These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 4136737)

  • 1. Five years' experience with iodine-125 therapy of Graves' disease.
    Weidinger P; Johnson PM; Werner SC
    Lancet; 1974 Jul; 2(7872):74-7. PubMed ID: 4136737
    [No Abstract]   [Full Text] [Related]  

  • 2. Hypothyroidism following iodine-131 therapy.
    Hayes MT
    J Nucl Med; 1982 Feb; 23(2):176-9. PubMed ID: 6173470
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of therapy on serum thyroglobulin levels in patients with Graves' disease.
    Uller RP; Van Herle AJ
    J Clin Endocrinol Metab; 1978 May; 46(5):747-55. PubMed ID: 95586
    [No Abstract]   [Full Text] [Related]  

  • 4. Serum thyroglobulin in normal subjects and patients with hyperthyroidism due to Graves' disease: effects of T3, iodide, 131I and antithyroid drugs.
    Gardner DF; Rothman J; Utiger RD
    Clin Endocrinol (Oxf); 1979 Dec; 11(6):585-94. PubMed ID: 93993
    [No Abstract]   [Full Text] [Related]  

  • 5. Graves' Disease: Can It Be Cured?
    Wiersinga WM
    Endocrinol Metab (Seoul); 2019 Mar; 34(1):29-38. PubMed ID: 30912336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Combination of low doses of 131-iodine and synthetic antithyroid agents for prolonged treatment in Basedow's disease. Apropos of 165 cases].
    Mitouze J; Jaffiol C; Baldet L; Ghachem M
    Rev Fr Endocrinol Clin; 1972; 13(4):339-61. PubMed ID: 4122472
    [No Abstract]   [Full Text] [Related]  

  • 7. Low-dosage 131-I therapy of thyrotoxicosis (diffuse goiters). A five-year follow-up study.
    Cevallos JL; Hagen GA; Maloof F; Chapman EM
    N Engl J Med; 1974 Jan; 290(3):141-3. PubMed ID: 4859623
    [No Abstract]   [Full Text] [Related]  

  • 8. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease.
    Chen JJ; Ladenson PW
    J Clin Endocrinol Metab; 1986 Jul; 63(1):102-6. PubMed ID: 2423547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficiency analysis of using tailored individual doses of radioiodine and fine tuning using a low-dose antithyroid drug in the treatment of Graves' disease.
    Liu CJ; Dong YY; Wang YW; Wang KH; Zeng QY
    Nucl Med Commun; 2011 Mar; 32(3):227-32. PubMed ID: 21191313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithyroid drugs as a factor influencing the outcome of radioiodine therapy in Graves' disease and toxic nodular goitre?
    Körber C; Schneider P; Körber-Hafner N; Hänscheid H; Reiners C
    Eur J Nucl Med; 2001 Sep; 28(9):1360-4. PubMed ID: 11585295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: one-year follow-up of a prospective, randomized study.
    Andrade VA; Gross JL; Maia AL
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3488-93. PubMed ID: 11502768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up study of compensated low-dose 131I therapy for Graves' disease.
    Sridama V; McCormick M; Kaplan EL; Fauchet R; DeGroot LJ
    N Engl J Med; 1984 Aug; 311(7):426-32. PubMed ID: 6205272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease.
    Alexander EK; Larsen PR
    J Clin Endocrinol Metab; 2002 Mar; 87(3):1073-7. PubMed ID: 11889166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithyroid drug treatment prior to radioiodine therapy for Graves' disease: yes or no?
    Bogazzi F; Martino E; Bartalena L
    J Endocrinol Invest; 2003 Feb; 26(2):174-6. PubMed ID: 12739747
    [No Abstract]   [Full Text] [Related]  

  • 15. T lymphocyte subpopulations in Graves' disease: relationship with clinical conditions.
    Bagnasco M; Canonica GW; Ferrini S; Biassoni P; Melioli G; Ferrini O; Giordano G
    Acta Endocrinol (Copenh); 1983 Feb; 102(2):213-9. PubMed ID: 6187169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triiodothyronine suppression tests and TSH-releasing hormone tests before and after I- 131 therapy for Graves' disease.
    Tamai H; Nakagawa T; Takahashi H; Ohsako N; Fukino O; Shinzato R; Suematsu H; Matsuzuka F; Kuma K; Nagataki S
    J Nucl Med; 1980 Mar; 21(3):240-5. PubMed ID: 6892713
    [No Abstract]   [Full Text] [Related]  

  • 17. Predictive factors for early hypothyroidism following the radioactive iodine therapy in Graves' disease patients.
    Hu RT; Liu DS; Li B
    BMC Endocr Disord; 2020 May; 20(1):76. PubMed ID: 32471411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
    Franklyn JA; Daykin J; Holder R; Sheppard MC
    QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperthyroidism due to Graves-Basedow disease in a woman refractory to thyroid hormones.
    González Cabrera N; Kalic AK; Antón Miguel MÁ; Sierra Polo P; Vicente Vicente MÁ
    Endocrinol Nutr; 2012 Dec; 59(10):609-11. PubMed ID: 22425314
    [No Abstract]   [Full Text] [Related]  

  • 20. 125I therapy in Graves' disease. Long-term results in 355 patients.
    McDougall IR; Greig WR
    Ann Intern Med; 1976 Dec; 85(6):720-3. PubMed ID: 1036667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.